MGTX Stock Forecast: MeiraGTx Holdings Plc Price Predictions for 2026-2027
The 8 Wall Street analysts covering MeiraGTx Holdings Plc hold a median 12-month price target of $24 — +194.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 70 of 100 as at 21 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores MeiraGTx Holdings Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Accruals (7): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MGTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MGTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +194.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2026 | Goldman Sachs | Initiates | Neutral | $16 |
| 14 Aug 2026 | RBC Capital | Maintains | Outperform | $26 → $27 |
| 8 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 8 July 2026 | RBC Capital | Maintains | Outperform | $25 → $26 |
| 15 May 2026 | RBC Capital | Maintains | Outperform | — |
| 22 Apr 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Apr 2026 | RBC Capital | Maintains | Outperform | — |
| 1 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 27 Mar 2026 | B of A Securities | Maintains | Buy | — |
| 27 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 27 Mar 2026 | Piper Sandler | Maintains | Overweight | — |
| 24 Nov 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 14 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 14 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 11 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
| 21 Oct 2025 | Raymond James | Initiates | Strong Buy | — |
| 15 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 14 May 2025 | Chardan Capital | Maintains | Buy | — |
| 17 Mar 2025 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MGTX.
This page is one stock. Monday covers all of them.
MGTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MGTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, MeiraGTx Holdings Plc returned +7.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MGTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 9.2×
- Price / sales
- 1.9×
- Price / book
- 3.6×
- EV / EBITDA
- 3.8×
Cheaper than 76% of US stocks
Cheaper than 49% of US stocks
Cheaper than 26% of US stocks
Cheaper than 86% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 97.8%
- Operating margin
- 44.8%
- Net margin
- 19.5%
Higher than 99% of US stocks
Higher than 95% of US stocks
Higher than 81% of US stocks
- Return on equity
- 89.5%
- Return on assets
- 37.5%
- Dividend yield
- —
Higher than 96% of US stocks
Higher than 99% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MeiraGTx Holdings Plc has a market value of $779.9M and an enterprise value of $729.2M.
Revenue in the twelve months to 30 June 2026: $397.5M. The latest quarter grew 8608.6% year on year.
Net income over the same four quarters: $78.9M, a 19.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$14.2M.
Trailing P/E: 9.2×.
MeiraGTx Holdings Plc employs 386 people — $1.0M of revenue per employee.
Data provided by Twelve Data
MGTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MGTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own MeiraGTx Holdings Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MGTX
What is the MGTX stock price forecast for 2026-2027?
The 8 Wall Street analysts covering MeiraGTx Holdings Plc have a median 12-month price target of $24, with estimates ranging from $16 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MGTX stock a buy right now?
Of the 8 analysts covering MeiraGTx Holdings Plc, 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MeiraGTx Holdings Plc 70 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MGTX?
As at 21 Nov 2026, MeiraGTx Holdings Plc ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
Will MGTX stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +194.5% from the last close, and Ticker Nerd's factor model ranks MeiraGTx Holdings Plc 70 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MGTX stock forecast for 2030?
No analyst covering MeiraGTx Holdings Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $50 over the next 12 months.
How has MGTX stock performed over the past year?
MeiraGTx Holdings Plc returned +7.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does MeiraGTx Holdings Plc do?
MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing gene and cell therapies for serious inherited and acquired diseases. MeiraGTx Holdings plc uses a vertically integrated model that combines discovery, development, and manufacturing capabilities to support its genetic medicine programs.
About MeiraGTx Holdings Plc.
MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing gene and cell therapies for serious inherited and acquired diseases. MeiraGTx Holdings plc uses a vertically integrated model that combines discovery, development, and manufacturing capabilities to support its genetic medicine programs. Its current pipeline targets conditions in the eye, salivary gland, and central nervous system, including retinal disorders, radiation-induced xerostomia, and Parkinson’s disease. The company’s work centers on local delivery of small doses designed to produce disease-modifying effects in areas of high unmet medical need. MeiraGTx Holdings plc operates as part of the biotechnology and health technology market, where it contributes to the advancement of precision therapies built around genetic intervention.
CEO Dr. Alexandria Forbes Ph.D. · 386 employees · United States · https://www.meiragtx.com